Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Medartis Holding stock

MED.SW
CH0386200239
A2JGBF

Price

61.00
Today +/-
+1.60
Today %
+2.49 %

Medartis Holding stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Medartis Holding stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Medartis Holding stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Medartis Holding stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Medartis Holding's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Medartis Holding Stock Price History

DateMedartis Holding Price
1/9/202561.00 undefined
1/8/202559.50 undefined
1/7/202560.00 undefined
1/6/202560.00 undefined
1/3/202557.70 undefined
12/30/202456.60 undefined
12/27/202459.60 undefined
12/23/202453.50 undefined
12/20/202451.20 undefined
12/19/202454.40 undefined
12/18/202453.50 undefined
12/17/202454.70 undefined
12/16/202454.20 undefined
12/13/202454.50 undefined
12/12/202454.10 undefined

Medartis Holding Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Medartis Holding, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Medartis Holding from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Medartis Holding’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Medartis Holding. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Medartis Holding’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Medartis Holding’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Medartis Holding’s growth potential.

Medartis Holding Revenue, EBIT and net profit per share

DateMedartis Holding RevenueMedartis Holding EBITMedartis Holding Net Income
2027e367.61 M undefined37.73 M undefined0 undefined
2026e338.7 M undefined31.87 M undefined22.24 M undefined
2025e281.54 M undefined22.99 M undefined13.65 M undefined
2024e244.93 M undefined15.82 M undefined10.56 M undefined
2023212.01 M undefined9.68 M undefined619,000 undefined
2022182.82 M undefined-1.87 M undefined-5.78 M undefined
2021159.88 M undefined11.01 M undefined6.84 M undefined
2020127.65 M undefined3.1 M undefined-943,570 undefined
2019130.14 M undefined7.35 M undefined2.15 M undefined
2018121.32 M undefined6.06 M undefined4.2 M undefined
2017105.04 M undefined9.61 M undefined866,520 undefined
201692.5 M undefined7.23 M undefined3.31 M undefined
201582.3 M undefined12.15 M undefined7.27 M undefined

Medartis Holding Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e2027e
8292105121130127159182212244281338367
-12.2014.1315.247.44-2.3125.2014.4716.4815.0915.1620.288.58
82.9382.6182.8683.4785.3883.4684.2881.8778.7768.4459.4349.4145.50
6876871011111061341491670000
7304206-501013220
--57.14---50.00---183.33--30.0069.23-
11.7411.7411.7410.6311.7411.7711.811.8312.230000
-------------
Details

Keystats

Revenue and Growth

The Medartis Holding Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Medartis Holding is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201520162017201820192020202120222023
                 
1.351.761.97116.2699.5782.7382.6420.625.2
12.2315.1719.3720.9726.3924.1932.539.9340.48
0.872.923.944.274.13.253.575.045.88
26.5229.1135.0337.9547.1649.5654.369.968.3
11.641.763.273.671.382.462.411.56
41.9750.662.07182.73180.88161.11175.48137.88141.42
30.9530.9332.7437.0467.6869.5264.5679.2880.07
0.131.781.011.091.0410.8116.5915.4334.26
0000003.885.040
1.351.44.745.99.268.839.3731.4429.37
003.633.33.192.612.5538.5535.28
30.5930.5426.3125.7426.4529.9129.6325.3129.14
63.0264.6568.4373.08107.63121.69126.58195.05208.11
104.99115.25130.49255.8288.51282.79302.06332.93349.53
                 
1.181.461.462.352.352.362.362.372.47
000000000
-48.2512.9412.51212.69210.02208.62220.07234.59257.57
2.092.713.073.23.22.061.560.81-5.08
000000000
-44.9817.117.04218.23215.57213.04224237.78254.96
4.216.346.666.6310.745.738.249.68.24
2.161.621.261.621.987.4613.999.4811.52
4.457.7310.9810.213.467.957.8914.8311.04
0000000461.71462
3.752.5512.411.723.924.524.595.1614.69
14.5718.2531.3120.1830.125.6634.7139.5345.96
75.9862.1362.161.6522.522.6619.4946.4235.41
2.893.173.710.170.10.040.010.110.2
56.5314.5916.2715.5720.2321.419.984.0613.01
135.4179.8982.1517.3942.8344.139.4850.5948.62
149.9798.14113.4537.5772.9469.7674.1890.1194.58
104.99115.25130.49255.8288.51282.79298.18327.89349.53
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Medartis Holding provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Medartis Holding's financial health and stability.

Assets

Medartis Holding's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Medartis Holding must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Medartis Holding after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Medartis Holding's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201520162017201820192020202120222023
7304206-50
66781215161822
0000000-20
-5-7-6-7-11-2-6-19-2
38915043-1
1,00000000000
022300005
111111691220-319
-11-8-8-14-19-13-10-18-18
-9-8-16-14-19-22-15-52-37
1,0000-7,00000-9,000-5,000-34,000-19,000
000000000
-2-25-12-4-3-4-5-5
000142000129
-2-25122-5-4-4-323
----7.00-----
000000000
000114-16-160-624
0.823.382.22-8.03-10.42-0.4510.61-22.721.17
000000000

Medartis Holding stock margins

The Medartis Holding margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Medartis Holding. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Medartis Holding.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Medartis Holding's sales revenue. A higher gross margin percentage indicates that the Medartis Holding retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Medartis Holding's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Medartis Holding's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Medartis Holding's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Medartis Holding. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Medartis Holding's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Medartis Holding Margin History

Medartis Holding Gross marginMedartis Holding Profit marginMedartis Holding EBIT marginMedartis Holding Profit margin
2027e79.04 %10.26 %0 %
2026e79.04 %9.41 %6.57 %
2025e79.04 %8.17 %4.85 %
2024e79.04 %6.46 %4.31 %
202379.04 %4.56 %0.29 %
202281.77 %-1.02 %-3.16 %
202183.88 %6.89 %4.28 %
202083.43 %2.43 %-0.74 %
201985.5 %5.65 %1.65 %
201883.26 %4.99 %3.46 %
201783.36 %9.15 %0.82 %
201682.16 %7.82 %3.58 %
201582.8 %14.76 %8.83 %

Medartis Holding Stock Sales Revenue, EBIT, Earnings per Share

The Medartis Holding earnings per share therefore indicates how much revenue Medartis Holding has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Medartis Holding earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Medartis Holding's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Medartis Holding’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Medartis Holding's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Medartis Holding Revenue, EBIT and net profit per share

DateMedartis Holding Sales per ShareMedartis Holding EBIT per shareMedartis Holding Earnings per Share
2027e27.03 undefined0 undefined0 undefined
2026e24.9 undefined0 undefined1.64 undefined
2025e20.7 undefined0 undefined1 undefined
2024e18.01 undefined0 undefined0.78 undefined
202317.33 undefined0.79 undefined0.05 undefined
202215.45 undefined-0.16 undefined-0.49 undefined
202113.55 undefined0.93 undefined0.58 undefined
202010.85 undefined0.26 undefined-0.08 undefined
201911.08 undefined0.63 undefined0.18 undefined
201811.42 undefined0.57 undefined0.4 undefined
20178.95 undefined0.82 undefined0.07 undefined
20167.88 undefined0.62 undefined0.28 undefined
20157.01 undefined1.03 undefined0.62 undefined

Medartis Holding business model

Medartis Holding AG is a Swiss company specializing in the development and manufacturing of implants and instruments for traumatology, hand and foot surgery, and upper and lower limb reconstruction. The company was founded in 1997 by a group of doctors who decided to develop innovative products that meet the needs of patients and surgeons. The business model of Medartis is based on the sale of implants and instruments developed in close collaboration with leading surgeons. The company places particular emphasis on the use of high-quality materials and high processing quality. With this philosophy, the company has quickly gained an excellent reputation, which is also reflected in the increasing demand for its products. The company is divided into various specialized areas, each offering specialized products and solutions. One of Medartis' main areas is traumatology, which specializes in the treatment of injuries and fractures. In this area, the company offers a variety of implants and instruments tailored to the needs of surgeons and patients. Products such as plates, screws, and nails ensure that bone fractures can be stabilized and healed. Another important area of Medartis is hand surgery. Here, the company has a wide portfolio of implants and instruments tailored to the specific requirements of hand operations. One of the well-known solutions is the finger fixator, a small but very effective device used in the treatment of finger fractures. In the field of foot surgery, Medartis also offers a variety of solutions. From implants for stabilizing ankle and foot joints to instruments for correcting deformities, the company has a broad range of products. Particularly noteworthy are the implants and instruments used in the treatment of hallux valgus, commonly known as bunions. In addition to these traditional areas, Medartis also has products and solutions in its portfolio specialized in the reconstruction of the upper and lower limbs. These include implants and instruments for the treatment of spinal injuries as well as solutions for the reconstruction of knee or hip joints. Overall, in recent years, Medartis has established itself as one of the leading providers of implants and instruments in the field of traumatology, hand and foot surgery, and upper and lower limb reconstruction. With its innovative product range and high-quality standards, the company has gained an excellent reputation that will continue to drive increasing demand in the future. Medartis Holding is one of the most popular companies on Eulerpool.com.

Medartis Holding SWOT Analysis

Strengths

1. Leading position in the market: Medartis Holding AG is a well-established company with a strong presence in the medical devices industry.

2. Broad product portfolio: The company offers a wide range of innovative and high-quality surgical solutions, catering to various medical specialties.

3. Strong research and development capabilities: Medartis invests significantly in R&D to develop new products and improve existing ones, ensuring its competitiveness in the market.

Weaknesses

1. Dependence on a limited number of markets: Medartis relies heavily on European and North American markets for its revenue, making it susceptible to any fluctuations or economic uncertainties in these regions.

2. Relatively high pricing: The premium quality and advanced technology of Medartis' products often lead to higher prices, which may limit accessibility for price-sensitive markets.

3. Limited brand recognition outside medical professionals: The company's brand awareness among the general public is relatively low, which may hinder its growth potential.

Opportunities

1. Emerging markets: Medartis can explore and expand its presence in the growing economies of Asia, Latin America, and other regions, where there is increasing demand for medical devices.

2. Technological advancements: The continuous advancements in surgical techniques and materials present opportunities for Medartis to develop and introduce innovative products.

3. Acquisitions and partnerships: The company can consider strategic collaborations or acquisitions to enhance its product offerings, enter new markets, or strengthen its market position.

Threats

1. Intense competition: Medartis faces competition from both established and emerging players in the medical devices market, which may impact its market share and pricing power.

2. Stringent regulations: The medical devices industry is subject to strict regulations and compliance requirements, which may increase costs and pose challenges in product development and commercialization.

3. Economic uncertainties: Macro-economic factors such as recessions or global economic downturns can adversely impact healthcare spending and affect Medartis' revenue.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Medartis Holding Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Medartis Holding historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Medartis Holding shares outstanding

The number of shares was Medartis Holding in 2024 — This indicates how many shares 12.232 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Medartis Holding earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Medartis Holding's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Medartis Holding’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Medartis Holding's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Medartis Holding.

Eulerpool ESG Scorecard© for the Medartis Holding stock

Eulerpool World ESG Rating (EESG©)

65/ 100

🌱 Environment

61

👫 Social

93

🏛️ Governance

42

Environment

Scope 1 - Direct Emissions
857
Scope 2 - Indirect emissions from purchased energy
604
Scope 3 - Indirect emissions within the value chain
5,395
Total CO₂ emissions
1,461
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees39.04
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Medartis Holding shareholders

%
Name
Stocks
Change
Date
41.38559 % Straumann (Thomas)5,628,440012/31/2023
11.65262 % Nordflint Capital Partners Fondsmaeglerselskab A/S1,584,756191,71812/31/2023
6.77232 % Ellenrieder (Dominik)921,035012/31/2023
6.27795 % Bank of America Corp853,801853,8014/5/2024
5.72307 % Endeavour Vision Ltd778,3372,15912/31/2023
4.54351 % Miesch (Willi)617,91704/9/2024
3.02254 % Pictet Asset Management Ltd.411,065162,2185/15/2024
0.95816 % Bank Vontobel AG (Private Banking)130,31007/31/2024
0.94323 % The Vanguard Group, Inc.128,2792,8669/30/2024
0.67513 % Deka Investment GmbH91,81719,0666/30/2024
1
2
3
4
5
...
8

Medartis Holding Executives and Management Board

Mr. Christoph Broennimann

(56)
Medartis Holding Chief Executive Officer, Member of the Executive Management Board
Compensation 1.85 M

Mr. Marco Gadola

(59)
Medartis Holding Non-Executive Independent Chairman of the Board
Compensation 544,943

Dr. H. C. Straumann

(59)
Medartis Holding Non-Executive Vice Chairman of the Board (since 1998)
Compensation 292,302

Ms. Nadia Schmidt

(50)
Medartis Holding Non-Executive Independent Member of the Board
Compensation 164,145

Mr. Willi Miesch

(58)
Medartis Holding Non-Executive Member of the Board (since 1998)
Compensation 161,736
1
2
3

Most common questions regarding Medartis Holding

What values and corporate philosophy does Medartis Holding represent?

Medartis Holding AG represents a strong set of values and corporate philosophy. The company is committed to innovation, quality, and patient-oriented solutions in the field of medical technology. Medartis focuses on designing and manufacturing surgical implants for orthopedic and traumatology applications, catering to the needs of surgeons and patients alike. With a dedication to continuous improvement and customer satisfaction, Medartis aims to provide advanced and reliable implant systems that enhance patient outcomes and promote faster recovery. The company's steadfast commitment to excellence, along with its customer-centric approach, makes Medartis Holding AG a trusted name in the medical technology industry.

In which countries and regions is Medartis Holding primarily present?

Medartis Holding AG is primarily present in Switzerland and operates internationally. As a leading manufacturer of medical devices, the company provides innovative solutions for surgical fixation of bone fractures and osteotomies. With its headquarters in Basel, Medartis has a strong presence in Europe and a growing global footprint, serving healthcare professionals and patients across various countries and regions. The company's commitment to quality, research, and patient care has cemented its reputation as a trusted partner in the orthopedic industry.

What significant milestones has the company Medartis Holding achieved?

Medartis Holding AG, a leading medical technology company, has achieved several significant milestones. The company has successfully developed and launched innovative surgical solutions, enhancing patient outcomes worldwide. Medartis Holding AG has expanded its global presence, establishing a strong market position in various regions. The company's commitment to research and development has led to the introduction of state-of-the-art implants and instruments, revolutionizing the field of orthopedic surgery. Medartis Holding AG continues to collaborate with renowned healthcare professionals, ensuring continuous advancements in its product offerings. Through its dedication to excellence and persistent pursuit of innovation, Medartis Holding AG remains at the forefront of the medical technology industry.

What is the history and background of the company Medartis Holding?

Medartis Holding AG is a renowned Swiss-based medical device company specializing in innovative surgical solutions for orthopedic and traumatology procedures. Founded in 1997, Medartis has established itself as a global leader in providing high-quality implants, instruments, and services to healthcare professionals. With a strong focus on research and development, the company offers a wide range of products designed to enhance patient outcomes and simplify surgical procedures. Medartis Holding AG's commitment to innovation, advanced technology, and collaboration with healthcare communities worldwide has solidified its position as a trusted partner in the field of orthopedic and traumatology surgery.

Who are the main competitors of Medartis Holding in the market?

Medartis Holding AG faces competition from various companies in the market. Some of its main competitors include industry leaders in the medical devices sector, such as Zimmer Biomet Holdings, Stryker Corporation, and Johnson & Johnson. These companies also operate in the orthopedic implants industry, offering similar products and solutions to healthcare professionals and patients. Medartis Holding AG strives to differentiate itself through its innovative product offerings and dedication to quality and customer satisfaction. However, it continues to face fierce competition from these renowned players within the industry.

In which industries is Medartis Holding primarily active?

Medartis Holding AG is primarily active in the medical technology industry.

What is the business model of Medartis Holding?

Medartis Holding AG is a leading medical technology company that specializes in the development and manufacturing of innovative surgical solutions for orthopedic and trauma surgery. Their business model revolves around providing high-quality and innovative products such as implants, instruments, and digital solutions to surgeons and hospitals worldwide. By focusing on customer needs and leveraging their expertise, Medartis aims to improve patient outcomes and enhance surgical experiences. With a strong commitment to research and development, the company continues to drive innovation in the field of orthopedic surgery, ensuring its position as a trusted partner in the global healthcare industry.

What is the P/E ratio of Medartis Holding 2025?

The Medartis Holding P/E ratio is 54.65.

What is the P/S ratio of Medartis Holding 2025?

The Medartis Holding P/S ratio is 2.65.

What is the Quality Investing of Medartis Holding?

The Quality Investing for Medartis Holding is 4/10.

What is the revenue of Medartis Holding 2025?

The expected Medartis Holding revenue is 281.54 M CHF.

How high is the profit of Medartis Holding 2025?

The expected Medartis Holding profit is 13.65 M CHF.

What is the business model of Medartis Holding

The Medartis Holding AG is a Swiss company that specializes in the development, production, and distribution of implants and instruments for the surgical treatment of bone fractures and deformities. The company's business model focuses on providing products in the fields of traumatology, hand surgery, foot surgery, and maxillofacial surgery. The Medartis Holding AG offers a wide range of products, including implants such as plates, screws, Kirschner wires, and nails. These implants are made from titanium or stainless steel to ensure the highest strength and stability. Additionally, the company offers instruments to support surgical procedures, including drills, saws, forceps, and scissors. All products are developed and manufactured in Switzerland to ensure the highest quality standards. The traumatology division is a key focus of the business model as it targets the treatment of fractures, breaks, and defects of the skeletal system. Here, the company offers a wide range of implants and instruments specifically designed for different types and areas of bone, such as hip, shoulder, hand, and foot surgeries. In the field of hand surgery, the Medartis Holding AG offers products for the treatment of hand and wrist injuries, diseases, and defects. This includes specialized implants such as finger and thumb plates that enable fast and precise bone fracture repair. Additionally, the company also offers instruments specifically designed for working with delicate tissues such as tendons and nerves. In the field of foot surgery, the company provides solutions for injuries, diseases, and deformities of the foot and ankle. This includes implants such as screws for the treatment of ankle fractures and bone deformities, as well as plates for stabilizing fractures in the toe and midfoot areas. Maxillofacial surgery is another area that the business model of Medartis Holding AG focuses on. Here, the company offers a wide range of implants for the treatment of jawbone injuries, defects, and pathologies. This includes implants for stabilizing bone fractures and for the reconstruction and regeneration of jawbone. In addition to its products, the company also offers training and educational programs for surgeons and medical professionals to ensure that its technology remains up to date and that its products can be used safely and effectively. Overall, the business model of Medartis Holding AG is based on the development and provision of high-quality implants and instruments for the treatment of bone fractures and deformities in various medical fields. Through its innovative products and solutions, the company has become a key player in the medical industry and will continue to play an important role in the future.

What is the Medartis Holding dividend?

Medartis Holding pays a dividend of 0 CHF distributed over payouts per year.

How often does Medartis Holding pay dividends?

The dividend cannot currently be calculated for Medartis Holding or the company does not pay out a dividend.

What is the Medartis Holding ISIN?

The ISIN of Medartis Holding is CH0386200239.

What is the Medartis Holding WKN?

The WKN of Medartis Holding is A2JGBF.

What is the Medartis Holding ticker?

The ticker of Medartis Holding is MED.SW.

How much dividend does Medartis Holding pay?

Over the past 12 months, Medartis Holding paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Medartis Holding is expected to pay a dividend of 0 CHF.

What is the dividend yield of Medartis Holding?

The current dividend yield of Medartis Holding is .

When does Medartis Holding pay dividends?

Medartis Holding pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Medartis Holding?

Medartis Holding paid dividends every year for the past 0 years.

What is the dividend of Medartis Holding?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Medartis Holding located?

Medartis Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Medartis Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Medartis Holding from 1/10/2025 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 1/10/2025.

When did Medartis Holding pay the last dividend?

The last dividend was paid out on 1/10/2025.

What was the dividend of Medartis Holding in the year 2024?

In the year 2024, Medartis Holding distributed 0 CHF as dividends.

In which currency does Medartis Holding pay out the dividend?

The dividends of Medartis Holding are distributed in CHF.

All fundamentals about Medartis Holding

Our stock analysis for Medartis Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medartis Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.